Cytosorbents Corporation (CTSO): Price and Financial Metrics

Cytosorbents Corporation (CTSO): $8.41

0.18 (+2.19%)

POWR Rating

Component Grades














  • CTSO scores best on the Growth dimension, with a Growth rank ahead of 85.34% of US stocks.
  • CTSO's strongest trending metric is Value; it's been moving up over the last 199 days.
  • CTSO ranks lowest in Sentiment; there it ranks in the 21st percentile.

CTSO Stock Summary

  • For CTSO, its debt to operating expenses ratio is greater than that reported by just 4.97% of US equities we're observing.
  • With a year-over-year growth in debt of -97.05%, Cytosorbents Corp's debt growth rate surpasses just 1.35% of about US stocks.
  • Revenue growth over the past 12 months for Cytosorbents Corp comes in at 50.7%, a number that bests 89.9% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CTSO, based on their financial statements, market capitalization, and price volatility, are ICAD, LTRX, SBBP, FLDM, and AIRG.
  • Visit CTSO's SEC page to see the company's official filings. To visit the company's web site, go to

CTSO Price Target

For more insight on analysts targets of CTSO, see our CTSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.88 Average Broker Recommendation 1.36 (Strong Buy)

CTSO Stock Price Chart Interactive Chart >

Price chart for CTSO

CTSO Price/Volume Stats

Current price $8.41 52-week high $11.74
Prev. close $8.23 52-week low $7.13
Day low $8.25 Volume 202,900
Day high $8.52 Avg. volume 324,882
50-day MA $8.89 Dividend yield N/A
200-day MA $8.86 Market Cap 364.31M

Cytosorbents Corporation (CTSO) Company Bio

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.

CTSO Latest News Stream

Event/Time News Detail
Loading, please wait...

CTSO Latest Social Stream

Loading social stream, please wait...

View Full CTSO Social Stream

Latest CTSO News From Around the Web

Below are the latest news stories about Cytosorbents Corp that investors may wish to consider to help them evaluate CTSO as an investment opportunity.

CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q1 2021 Results - Earnings Call Transcript

CytoSorbents Corporation (CTSO) Q1 2021 Earnings Conference Call May 4, 2021 4:45 PM ET Company Participants Amy Vogel - Investor Relations Phillip Chan - Chief Executive Officer Efthymios Deliargyris - Chief Medical Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales and Marketing, Managing Director,...

SA Transcripts on Seeking Alpha | May 5, 2021

CytoSorbents Reports First Quarter 2021 Financial and Operational Results

CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader using its CytoSorb® blood purification technology to treat life-threatening conditions in critically-ill and cardiac surgery patients around the world, reports financial and operating results for the quarter ended March 31, 2021.

Yahoo | May 4, 2021

CytoSorbents Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 4, 2021 / CytoSorbents Corp. (NASDAQ:CTSO) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 4, 2021 at 4:45 PM Eastern Time.

Yahoo | May 4, 2021

CytoSorbents to Report Q1 2021 Operating and Financial Results

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2021 financial results after the market close on Tuesday, May 4, 2021 at 4:45PM EST.

Yahoo | April 27, 2021

FDA gives green light to CytoSorbents to begin U.S. STAR-T trial for ticagrelor removal

The FDA has granted conditional approval for CytoSorbents' (CTSO) investigational device exemption ((IDE)) application for the STAR-T trial for the removal of ticagrelor during cardiothoracic surgery to reduce perioperative bleeding complications.Based on this conditional approval, study initiation activities, can now commence, putting the study ahead of the internal schedule.Conditions for full IDE...

Seeking Alpha | April 19, 2021

Read More 'CTSO' Stories Here

CTSO Price Returns

1-mo -5.51%
3-mo -26.55%
6-mo 1.69%
1-year -20.28%
3-year 6.46%
5-year 86.89%
YTD 5.52%
2020 107.01%
2019 -52.35%
2018 24.31%
2017 19.27%
2016 -2.15%

Continue Researching CTSO

Want to see what other sources are saying about Cytosorbents Corp's financials and stock price? Try the links below:

Cytosorbents Corp (CTSO) Stock Price | Nasdaq
Cytosorbents Corp (CTSO) Stock Quote, History and News - Yahoo Finance
Cytosorbents Corp (CTSO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.732 seconds.